Starboard last year took a $1 billion stake in Pfizer, looking to turn the pharma around after alleged severe shortcomings by ...
As more United States drug price changes have come to light this month, it remains clear that companies are tamping down ...
Over the years, the U.S. Department of Justice (DOJ) has taken a host of drugmakers to task over alleged kickback payments ...
Pharmaceutical Technology on MSN2d
Pfizer settles Biohaven kickback claims case for $59.7mBiohaven, acquired by Pfizer in 2022, allegedly took doctors to high-end restaurants and paid speaker honoraria for ...
The pharmaceutical giant Pfizer will pay nearly $60 million to resolve charges that a company it acquired paid kickbacks so ...
The alleged violations occurred before Pfizer bought Biohaven and its migraine treatment three years ago for $11.6 billion.
Hosted on MSN1d
Pfizer agrees to pay nearly $60M to settle FCA allegationsWorld-recognized brand Pfizer has agreed to a nearly $60 million financial agreement to settle claims that a wholly-owned ...
Pfizer (PFE) closed the latest trading day at $26.75, indicating a -0.41% change from the previous session's end. The stock trailed the S&P 500, which registered a daily gain of 0.92%. At the same ...
Pfizer will pay $59.7 million to resolve charges that a company it acquired defrauded Medicare and other healthcare programs ...
Citi analyst Geoff Meacham lowered the firm’s price target on Pfizer (PFE) to $29 from $30 and keeps a Neutral rating on the shares. Ahead of ...
Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback